Slow-release composite membrane based on three-layer structure as well as preparation method and application of slow-release composite membrane
The three-layer sustained-release composite membrane, consisting of an inner layer of chitosan, a middle layer of lipid nanoparticles and ethyl cellulose to load the drug, and an outer layer of PLGA membrane, solves the problems of unstable drug release and tissue damage in post-tumor resection treatment. It achieves long-term slow release and firm adhesion of the drug, reducing side effects.
Patent Information
- Application Number
- CN202411076355.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-19
AI Technical Summary
Existing treatment methods for tumor resection have problems such as excessive damage to normal tissues due to the expanded resection area, severe side effects of systemic chemotherapy, and a lack of suitable local sustained-release carriers.
A three-layer sustained-release composite membrane is used, with an inner layer of chitosan, a middle layer of lipid nanoparticles and ethyl cellulose loaded with drugs, and an outer layer of PLGA membrane. It is prepared through a specific solvent and drying process to achieve slow drug release and strong adhesion.
This achieves long-term, slow release of the drug, reduces toxicity to normal tissues, avoids drug migration and shedding, and provides long-term effectiveness and safety for local treatment.
Smart Images

Figure HDA0004982383610000011 
Figure HDA0004982383610000012
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical preparations, and in particular to a sustained-release composite film based on a three-layer structure, and a preparation method and application thereof. Background Art
[0002] Tumors are one of the most lethal diseases today, and the clinical treatment effect and prognosis survival have not been ideal. According to data provided by the International Agency for Research on Cancer [IARC], in 2018, there were about 18 million new cases of tumors and 9.5 million tumor-related deaths, which seriously affected human health. At present, the main treatments for tumors are systemic chemotherapy, immunotherapy, radiotherapy, and surgical treatment. Among them, surgical resection is the preferred treatment for most early and mid-stage solid tumors. Although surgical resection can remove most of the diseased tissue, tumor cells often invade surrounding tissues in a form that is difficult to distinguish with the naked eye, so they cannot be completely removed, leading to postoperative recurrence. The current solution to this problem is usually to expand the scope of resection and combine systemic systemic chemotherapy to try to remove residual tumor cells. Obviously, this solution has obvious shortcomings: 1. Expanding the scope of resection is likely to cause further damage to normal tissues, seriously affecting the patient's postoperative recovery, and is more likely to cause fatal organ failure; 2. Non-targeted systemic systemic chemotherapy will cause certain damage to normal cells while killing cancer cells, resulting in strong side effects, such as gastrointestinal reactions, bone marrow suppression, etc., which make patients suffer.
[0003] Local treatment methods can effectively alleviate the above-mentioned problems caused by tumor resection. Local treatment refers to the use of technical means to locate and store drugs in the lesion site and slowly release therapeutic drugs for a long time. Since the drug is located at the resection site for release, it can specifically kill the residual tumor cells in the surrounding normal tissues; at the same time, the drug is concentrated in the local area and slowly released, and will not be widely distributed in large doses throughout the body. Therefore, compared with systemic chemotherapy, local treatment can effectively reduce the adverse reactions caused by nonspecific distribution of drugs, and can effectively delay local tumor recurrence and metastasis, and improve prognosis. Local sustained-release carriers are the key link in achieving the localized slow release of therapeutic drugs, and are a hot research object related to local treatment issues. The current local sustained-release carriers mainly include polymer microspheres, phase change gels, implantable carriers, drug-loaded films, etc. Since there is a wound surface after tumor resection, accompanied by bleeding, the implantable drug-loaded film is more suitable for use as a local sustained-release carrier. There is currently no commercially available film for postoperative treatment of tumors. Summary of the invention
[0004] The purpose of the present invention is to innovatively provide a sustained-release composite membrane based on a three-layer membrane structure, and a preparation method and application thereof, which can be used for local chemotherapy after tumor resection, reduce adverse drug reactions, and inhibit tumor recurrence, and the composite membrane of the present invention also has a hemostatic function. Compared with free drugs, the sustained-release composite membrane prepared by the present invention has a drug sustained-release function, and can slowly release drugs within a certain period of time to achieve a long-term therapeutic effect, while avoiding the serious toxic effects of high-dose drug shock on normal tissues. In addition, the sustained-release composite membrane of the present invention can firmly adhere to the wound surface, and no displacement, shedding, etc. will occur after a certain period of time (such as 14 days); the tissue around the adhesion site is in good condition, and no pathological changes such as redness and swelling will occur.
[0005] To this end, in a first aspect of the present invention, the present invention provides a drug sustained-release composite film, comprising:
[0006] An inner layer, the inner layer is an adhesive layer, and the inner layer comprises chitosan;
[0007] a middle layer, the middle layer comprising lipid nanoparticles and ethylcellulose, wherein the lipid nanoparticles are loaded with drugs;
[0008] The outer layer is a PLGA membrane.
[0009] The inventors of the present application have found that, in the drug sustained-release composite membrane of the present application, compared with conventional materials such as PLGA, when the middle layer is ethyl cellulose, the drug release effect is significantly better.
[0010] In some embodiments, the membrane material of the lipid nanoparticles is phospholipid.
[0011] In some embodiments, the membrane material of the lipid nanoparticles is egg yolk phosphatidylcholine.
[0012] In some embodiments, the membrane material of the lipid nanoparticles is egg yolk phosphatidylcholine E80.
[0013] In some embodiments, in the lipid nanoparticles, the mass ratio of the drug to the membrane material of the lipid nanoparticles is 1:50-3:50, preferably 2:50.
[0014] In some embodiments, the mass ratio of the drug to the ethyl cellulose is 1:50-3:50, preferably 2:50.
[0015] In some embodiments, the inner layer further comprises hydroxypropyl methylcellulose (HPMC) and gelatin.
[0016] In some embodiments, the mass ratio of the chitosan, the hydroxypropyl methylcellulose and the gelatin is 1:1:1.
[0017] In some embodiments, the drug is a lipid-soluble drug or a water-soluble drug.
[0018] In some embodiments, the drug is oxaliplatin.
[0019] In some embodiments, the molecular weight of the PLGA is 38,000-54,000, and PLA:PGA=50:50.
[0020] In some embodiments, the viscosity of the chitosan is 200-400 mPa.s.
[0021] In a second aspect of the present invention, the present invention provides a method for preparing the drug sustained-release composite film described in any technical solution of the first aspect, comprising:
[0022] (1) providing a PLGA solution and drying it to obtain a PLGA film, wherein the solvent of the PLGA solution is a volatile organic solvent;
[0023] (2) providing an ethyl cellulose solution, wherein the solvent of the ethyl cellulose solution is an organic solvent;
[0024] (3) adding the drug lipid nanoparticle lyophilized powder to the ethyl cellulose solution in step (2) to obtain a solution M;
[0025] (4) spreading the solution M obtained in step (3) on the PLGA film obtained in step (1), and obtaining a composite film after drying;
[0026] (5) providing a polymer solution and drying it to obtain a chitosan adhesion layer, wherein the polymer comprises chitosan;
[0027] (6) Bonding the chitosan adhesion layer obtained in step (5) to the composite film obtained in step (4) to obtain the drug sustained-release composite film.
[0028] In some embodiments, the drug lipid nanoparticle lyophilized powder is prepared by the following method:
[0029] 1) Providing a phospholipid aqueous solution and a drug aqueous solution;
[0030] 2) mixing and drying the phospholipid aqueous solution and the drug aqueous solution to obtain drug lipid nanoparticle lyophilized powder.
[0031] In some embodiments, in step (1), in the PLGA solution, the concentration of PLGA is 0.1-0.3 g / mL, preferably 0.2 g / mL.
[0032] In some embodiments, in step (2), the organic solvent is selected from ethanol, glycerol, medium chain triglycerides (MCT) or any combination thereof.
[0033] In some embodiments, the organic solvent is a mixed solvent of ethanol, glycerol and medium chain triglycerides.
[0034] In some embodiments, in the mixed solvent, the mass percentage concentration of the glycerol is 0.5-1%, and the mass percentage concentration of the medium-chain triglycerides is 2-3%. In some embodiments, in the mixed solvent, the mass percentage concentration of the glycerol is 0.5%, and the mass percentage concentration of the medium-chain triglycerides is 2%.
[0035] The inventors of the present application have found that, when preparing a sustained-release composite film, the present application can achieve regulation of drug release rate by changing the amount of glycerol and medium-chain triglycerides to adapt to different clinical drug dosage requirements, and has broad application prospects.
[0036] In some embodiments, in step (2), the concentration of ethyl cellulose in the ethyl cellulose solution is 45-55 mg / mL, preferably 50 mg / mL.
[0037] In some embodiments, in step (3), the concentration of the drug in the solution M is 1-3 mg / mL, preferably 2 mg / mL.
[0038] In some embodiments, in step (5), the polymer further comprises hydroxypropyl methylcellulose (HPMC) and gelatin.
[0039] In some embodiments, in the polymer solution, the mass percentage concentrations of the chitosan, the hydroxypropyl methylcellulose and the gelatin are independently 0.4%-0.6%, preferably 0.5%.
[0040] In some embodiments, in step (5), the solvent of the polymer solution is an aqueous acetic acid solution.
[0041] In some embodiments, the pH of the aqueous acetic acid solution is 3.
[0042] In some embodiments, in step 1), the concentration of the phospholipid in the phospholipid aqueous solution is 45-55 mg / mL, preferably 50 mg / mL.
[0043] In some embodiments, in step 1), the phospholipid is egg yolk phosphatidylcholine.
[0044] In some embodiments, the phospholipid is egg yolk phosphatidylcholine E80.
[0045] In some embodiments, in step 1), the concentration of the drug in the aqueous drug solution is 1-3 mg / mL, preferably 2 mg / mL.
[0046] In some embodiments, in step 1), the drug is a fat-soluble drug or a water-soluble drug.
[0047] In some embodiments, the drug is oxaliplatin.
[0048] In some embodiments, in step 2), the volume ratio of the phospholipid aqueous solution to the drug aqueous solution is 1:1.
[0049] In some embodiments, in step (1), the molecular weight of the PLGA is 38,000-54,000, and PLA:PGA=50:50.
[0050] In some embodiments, in step (1), the volatile organic solvent is selected from acetone, dichloromethane, chloroform or any combination thereof.
[0051] In some embodiments, the volatile organic solvent is acetone, dichloromethane or chloroform.
[0052] In some embodiments, in step (1), the drying is natural air drying.
[0053] In some embodiments, in step (4), the drying is oven drying, preferably oven drying at 47°C.
[0054] In some embodiments, in step (5), the viscosity of the chitosan is 200-400 mPa.s.
[0055] In some embodiments, in step (5), the drying is freeze-drying.
[0056] In some embodiments, in step (6), the bonding is achieved using an adhesive.
[0057] In some embodiments, the binder is the PLGA solution in step (1).
[0058] In some embodiments, in step 2), the drying is vacuum drying or freeze drying.
[0059] In the third aspect of the present invention, the present invention provides the use of the drug sustained-release composite film described in any technical solution of the first aspect or the drug sustained-release composite film prepared by the method described in any technical solution of the second aspect in one or more selected from the following (1)-(4):
[0060] (1) As a drug carrier;
[0061] (2) As a tissue engineering scaffold;
[0062] (3) for preparing a reagent for hemostasis;
[0063] (4) Used for preparing a reagent, wherein the reagent is used for postoperative treatment of a tumor. Preferably, the tumor is a tumor treated by the drug loaded by the drug sustained-release composite membrane. Preferably, the drug is oxaliplatin.
[0064] In a fourth aspect of the present invention, the present invention provides a drug sustained-release composite film as described in any technical solution of the first aspect or a drug sustained-release composite film prepared by the method as described in any technical solution of the second aspect, which is used for one or more selected from the following (1)-(4):
[0065] (1) As a drug carrier;
[0066] (2) As a tissue engineering scaffold;
[0067] (3) Used to stop bleeding;
[0068] (4) Used for postoperative treatment of tumors. Preferably, the tumor is a tumor treated by the drug loaded by the drug sustained-release composite membrane. Preferably, the drug is oxaliplatin.
[0069] In the fifth aspect of the present invention, the present invention provides a drug carrier and / or tissue engineering scaffold, which comprises the drug sustained-release composite membrane described in any technical solution of the first aspect or the drug sustained-release composite membrane prepared by the method described in any technical solution of the second aspect.
[0070] The present invention also provides a hemostasis method and / or a postoperative tumor treatment method, which comprises: applying the drug sustained-release composite film described in any technical solution of the first aspect or the drug sustained-release composite film prepared by the method described in any technical solution of the second aspect to the wound of the subject.
[0071] In the present invention, "treatment" generally refers to obtaining the desired pharmacological and / or physiological effects, including: (a) inhibiting the symptoms of a disease, i.e., preventing its development; or (b) alleviating the symptoms of a disease, i.e., causing regression of the disease or symptoms.
[0072] In the present invention, "subject" refers to a vertebrate. In certain embodiments, a vertebrate refers to a mammal. Mammals include, but are not limited to, livestock (such as cattle), pets (such as cats, dogs, and horses), primates, mice, and rats. In certain embodiments, a mammal refers to a human.
[0073] Advantageous Effects of the Invention
[0074] 1: The sustained-release composite film of the present invention is used at room temperature and can release drugs in one direction.
[0075] 2: The sustained-release composite membrane of the present invention can be used as a drug carrier and a tissue engineering scaffold.
[0076] 3: The sustained-release composite membrane of the present invention has good biocompatibility and can carry water-soluble drugs or fat-soluble drugs.
[0077] 4: The sustained-release composite film of the present invention can achieve both adhesion hemostasis and therapeutic effects.
[0078] 5: The sustained-release composite membrane of the present invention can be used for local chemotherapy after tumor resection to reduce adverse drug reactions and inhibit tumor recurrence. The composite membrane of the present invention also has a hemostatic function.
[0079] 6: Compared with free drugs, the sustained-release composite film prepared by the present invention has a drug sustained-release function, which can slowly release drugs within a certain period of time to achieve a long-term therapeutic effect, while avoiding the serious toxic effects of high-dose drug shock on normal tissues.
[0080] 7: The sustained-release composite film of the present invention can firmly adhere to the wound surface, and will not shift or fall off after a certain period of time (such as 14 days); the tissue around the adhesion site is in good condition, and no pathological changes such as redness and swelling will occur. BRIEF DESCRIPTION OF THE DRAWINGS
[0081] Figure 1 This is a graph showing the cumulative release rate of oxaliplatin encapsulated in the sustained-release composite membrane according to an embodiment of the present invention;
[0082] Figure 2 This is an in vivo adhesion experiment of the sustained-release composite film of an embodiment of the present invention. DETAILED DESCRIPTION
[0083] Embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings and examples, but it will be appreciated by those skilled in the art that the following drawings and examples are only used to illustrate the present invention, rather than to limit the scope of the present invention. Various objects and advantages of the present invention will become apparent to those skilled in the art based on the following detailed description of the accompanying drawings and preferred embodiments.
[0084] The present invention discloses a sustained-release composite membrane based on reverse-phase lipid nanoparticles, a preparation method and a use thereof. The preparation method comprises the following steps: [1] preparing an E80 phospholipid solution of a certain concentration, and beating the solution with a homogenizer to obtain a solution A; [2] preparing an oxaliplatin solution of a certain concentration to obtain a solution B; [3] quantitatively mixing the solution A and the solution B, and freeze-drying the mixture to obtain a freeze-dried oxaliplatin powder; [4] preparing a PLGA solution with a volatile solvent to obtain a solution C, and quantitatively spreading the solution C on a mold, and drying the mixture naturally to obtain a PLGA membrane; [5] 】Ethyl cellulose was dissolved in a mixed solution of ethanol, glycerol and MCT to obtain solution D, oxaliplatin freeze-dried powder was added to obtain solution E, solution E was quantitatively spread on the PLGA membrane, and dried at 47°C to obtain composite membrane A; [6] Chitosan, HPMC and gelatin were dissolved in an acetic acid solution with a pH of 3 to obtain solution F, which was quantitatively spread on a mold and freeze-dried to obtain a chitosan adhesion layer; [7] The chitosan adhesion layer and composite membrane A were bonded together using solution C as an adhesive to obtain a three-layer structured sustained-release composite membrane. The sustained-release composite membrane of the present invention can be used as a drug carrier, has good biocompatibility, and can carry fat-soluble drugs.
[0085] In some embodiments, the present invention provides a method for preparing a sustained-release composite film based on a three-layer structure, which is characterized by comprising the following steps:
[0086] 【1】Prepare a 50 mg / ml E80 phospholipid solution and blend it with a homogenizer to obtain solution A;
[0087] 【2】Prepare an oxaliplatin solution with a concentration of 2 mg / ml to obtain solution B;
[0088] 【3】mixing solution A and solution B in a volume ratio of 1:1, and vacuum drying to obtain oxaliplatin lyophilized powder;
[0089] 【4】Prepare a PLGA solution with a concentration of 0.2 g / ml using a volatile solvent as solution C, spread 0.35 ml of solution C on a mold, and dry it naturally to obtain a PLGA film;
[0090] 【5】Ethanol, glycerol, and MCT mixed solution were used as solvents to prepare a 50 mg / ml ethyl cellulose solution to obtain solution D, to which oxaliplatin freeze-dried powder was added to obtain solution E with an oxaliplatin concentration of 2 mg / ml. 150 μl of solution E was spread on the PLGA membrane and dried at 47°C to obtain composite membrane A.
[0091] [6] Dissolve 0.5% chitosan, 0.5% HPMC, and 0.5% gelatin in an acetic acid solution with a pH of 3 to obtain a solution F, spread a certain amount on a mold, and freeze-dry to obtain a chitosan adhesion layer. For example, spread 0.4 g on a mold, and use a vacuum dryer to freeze-dry to obtain a chitosan adhesion layer;
[0092] 【7】Use 20 μl of solution C as an adhesive to bond the chitosan adhesive layer and the composite film A together to obtain a three-layer sustained-release composite film;
[0093] Optionally, the method further comprises the steps of:
[0094] 【8】In vitro release of three-layer composite sustained-release membrane
[0095] Place the composite membrane in 20 ml of release medium (PBS), place the release medium (PBS) containing the composite membrane on a constant temperature shaker at 37°C and 50 r / min, take samples at fixed points at 1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h, 96h, and 120h, centrifuge at 10000 r / min, and analyze the samples.
[0096] 【9】Detection
[0097] The samples were tested by high performance liquid chromatography; wherein the conditions of the high performance liquid chromatography were as follows:
[0098] The chromatographic column was Shiseido C18, with a column size of 250x4.6mm; column temperature: 40°C; mobile phase: aqueous phase was 10% phosphoric acid solution diluted 6000 times with distilled water, and the organic phase was methanol; elution procedure: isocratic elution of aqueous phase and organic phase at a volume ratio of 98:2; mobile phase flow rate 1ml / min; injection volume: 20μl; UV detector: detection wavelength: 248nm;
[0099]
[10] In vivo adhesion test
[0100] A 1.5 cm wound was cut in the abdomen of BALB / c mice, the liver lobe was gently pulled out, and a 0.3 cm wound was cut on the surface of the liver lobe. The composite film was attached to the bleeding wound of the mouse liver lobe and pressed for 30 seconds. The abdominal wound was sutured. The mice were dissected after 14 days to observe the adhesion.
[0101] In some embodiments, the volatile organic solvent is acetone, dichloromethane, or chloroform.
[0102] In some embodiments, the PLGA molecular weight is 38000-54000, 50 / 50.
[0103] In some embodiments, the chitosan has a viscosity of 200-400 mPa.s.
[0104] In other embodiments, the present invention provides a sustained-release composite film based on a three-layer structure prepared by the above method.
[0105] In other embodiments, the present invention provides a use of a sustained-release composite film based on a three-layer structure.
[0106] The present invention is now described with reference to the following examples which are intended to illustrate the present invention (but not to limit the present invention). Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents used in the embodiments of the present invention are commercially available.
[0107] The present invention is further described below in conjunction with specific embodiments.
[0108] Example 1
[0109] A method for preparing a sustained-release composite film based on a three-layer structure comprises the following steps:
[0110] 1. Preparation of oxaliplatin lipid nanoparticles lyophilized powder
[0111] (1) preparing a 50 mg / ml E80 phospholipid solution and blending it with a homogenizer to obtain solution A;
[0112] (2) preparing an oxaliplatin solution with a concentration of 2 mg / ml to obtain solution B;
[0113] (3) mixing solution A and solution B in a volume ratio of 1:1, and vacuum drying to obtain oxaliplatin lipid nanoparticle lyophilized powder;
[0114] 2. Preparation of three-layer composite sustained-release membrane
[0115] (1) preparing a PLGA solution with a concentration of 0.2 g / ml using acetone as solution C, spreading 0.35 ml of solution C on a mold, and drying it naturally to obtain a PLGA film;
[0116] (2) using a mixed solution of ethanol, MCT, and glycerol (ethanol: MCT: glycerol = 97.5:2:0.5) as a solvent, dissolving ethyl cellulose to obtain a solution D with an ethyl cellulose concentration of 50 mg / ml, adding the above-prepared oxaliplatin freeze-dried powder to obtain a solution E with an oxaliplatin concentration of 2 mg / ml, spreading 0.15 ml of the solution E on the PLGA membrane, and drying at 47°C to obtain a composite membrane A;
[0117] (3) dissolving 0.5% chitosan, 0.5% HPMC, and 0.5% gelatin in an acetic acid solution with a pH of 3 to obtain a solution F, spreading 0.4 g of the solution on a mold, and freeze-drying the solution in a vacuum dryer to obtain a chitosan adhesion layer;
[0118] (4) using 20 μl of solution C as an adhesive to bond the chitosan adhesive layer and the composite film A together to obtain a three-layer sustained-release composite film;
[0119] 3. In vitro release of three-layer composite sustained-release membrane
[0120] Place the composite membrane in 20 ml of release medium (PBS), place the release medium (PBS) containing the composite membrane on a constant temperature shaker at 37°C and 50 r / min, take samples at fixed points at 1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h, 96h, and 120h, centrifuge at 10000 r / min, and analyze the samples.
[0121] 4. Detection
[0122] The above samples were tested by high performance liquid chromatography; wherein the conditions of the high performance liquid chromatography were as follows:
[0123] The chromatogram was a Shiseido C18 column with a specification of 250x4.6mm; column temperature: 40°C; mobile phase: the aqueous phase was a 10% phosphoric acid solution diluted 6000 times with distilled water, and the organic phase was methanol; elution procedure: isocratic elution of the aqueous phase and the organic phase at a volume ratio of 98:2; mobile phase flow rate was 1mL / min; injection volume: 20μL; an ultraviolet detector was used: detection wavelength: 248nm.
[0124] Test results such as Figure 1 As shown. Figure 1 It can be seen that compared with free drugs, the sustained-release composite film prepared by the present invention has a drug sustained-release function, and can slowly release drugs within a certain period of time to achieve a long-term therapeutic effect, while avoiding the serious toxic effects of high-dose drug shock on normal tissues.
[0125] 5. In vivo adhesion test
[0126] A 1.5 cm wound was cut in the abdomen of BALB / c mice, the liver lobe was gently pulled out, and a 0.3 cm wound was cut on the surface of the liver lobe. The composite film was attached to the bleeding wound of the mouse liver lobe and pressed for 30 seconds. The abdominal wound was sutured. The mice were dissected after 14 days to observe the adhesion.
[0127] The results showed that the sustained-release composite film prepared by the present invention could firmly adhere to the wound surface, and no displacement or shedding occurred after 14 days; the liver tissue around the adhesion site was in good condition, and no pathological changes such as redness and swelling occurred.
[0128] Example 2
[0129] A method for preparing a sustained-release composite film based on a three-layer structure comprises the following steps:
[0130] 1. Preparation of oxaliplatin lipid nanoparticles lyophilized powder
[0131] (1) preparing a 50 mg / ml E80 phospholipid solution and blending it with a homogenizer to obtain solution A;
[0132] (2) preparing an oxaliplatin solution with a concentration of 2 mg / ml to obtain solution B;
[0133] (3) mixing solution A and solution B in a volume ratio of 1:1, and vacuum drying to obtain oxaliplatin lipid nanoparticle lyophilized powder;
[0134] 2. Preparation of three-layer composite sustained-release membrane
[0135] (1) preparing a PLGA solution with a concentration of 0.2 g / ml in dichloromethane as solution C, spreading 0.35 ml of solution C on a mold, and drying it naturally to obtain a PLGA film;
[0136] (2) using a mixed solution of ethanol, MCT, and glycerol (ethanol: MCT: glycerol = 96.5:3:0.5) as a solvent, dissolving ethyl cellulose to obtain a solution D with an ethyl cellulose concentration of 50 mg / ml, adding the above-prepared oxaliplatin freeze-dried powder to obtain a solution E with an oxaliplatin concentration of 2 mg / ml, spreading 0.15 ml of the solution E on the PLGA membrane, and drying at 47°C to obtain a composite membrane A;
[0137] (3) dissolving 0.5% chitosan, 0.5% HPMC, and 0.5% gelatin in an acetic acid solution with a pH of 3 to obtain a solution F, spreading 0.4 g of the solution on a mold, and freeze-drying the solution in a vacuum dryer to obtain a chitosan adhesion layer;
[0138] (4) using 20 μl of solution C as an adhesive to bond the chitosan adhesive layer and the composite film A together to obtain a three-layer sustained-release composite film;
[0139] 3. In vitro release of three-layer composite sustained-release membrane
[0140] The composite membrane was placed in 20 ml of release medium (PBS), and the release medium (PBS) containing the composite membrane was placed in a constant temperature shaker at 37°C and 50 r / min. Samples were taken at fixed points at 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, 48 h, 72 h, 96 h, and 120 h, and centrifuged at 10,000 r / min for sample analysis.
[0141] 4. Detection
[0142] The above samples were tested by high performance liquid chromatography; wherein the conditions of the high performance liquid chromatography were as follows:
[0143] The chromatogram was a Shiseido C18 column with a specification of 250x4.6mm; column temperature: 40°C; mobile phase: the aqueous phase was a 10% phosphoric acid solution diluted 6000 times with distilled water, and the organic phase was methanol; elution procedure: isocratic elution of the aqueous phase and the organic phase at a volume ratio of 98:2; mobile phase flow rate was 1mL / min; injection volume: 20μL; an ultraviolet detector was used: detection wavelength: 248nm.
[0144] Test results such as Figure 1 As shown. Figure 1 It can be seen that compared with free drugs, the sustained-release composite film prepared by the present invention has a drug sustained-release function, and can slowly release drugs within a certain period of time to achieve a long-term therapeutic effect, while avoiding the serious toxic effects of high-dose drug shock on normal tissues.
[0145] 5. In vivo adhesion test
[0146] A 1.5 cm wound was cut in the abdomen of BALB / c mice, the liver lobe was gently pulled out, and a 0.3 cm wound was cut on the surface of the liver lobe. The composite film was attached to the bleeding wound of the mouse liver lobe and pressed for 30 seconds. The abdominal wound was sutured. The mice were dissected after 14 days to observe the adhesion.
[0147] The results showed that the sustained-release composite film prepared by the present invention could firmly adhere to the wound surface, and no displacement or shedding occurred after 14 days; the liver tissue around the adhesion site was in good condition, and no pathological changes such as redness and swelling occurred.
[0148] Example 3
[0149] A method for preparing a sustained-release composite film based on a three-layer structure comprises the following steps:
[0150] 1. Preparation of oxaliplatin lipid nanoparticles lyophilized powder
[0151] (1) preparing a 50 mg / ml E80 phospholipid solution and blending it with a homogenizer to obtain solution A;
[0152] (2) preparing an oxaliplatin solution with a concentration of 2 mg / ml to obtain solution B;
[0153] (3) mixing solution A and solution B in a volume ratio of 1:1, and vacuum drying to obtain oxaliplatin lipid nanoparticle lyophilized powder;
[0154] 2. Preparation of three-layer composite sustained-release membrane
[0155] (1) preparing a PLGA solution with a concentration of 0.2 g / ml using chloroform as solution C, spreading 0.35 ml of solution C on a mold, and drying it naturally to obtain a PLGA film;
[0156] (2) Using a mixed solution of ethanol, MCT, and glycerol (ethanol: MCT: glycerol = 96:3:1) as a solvent, dissolving ethyl cellulose to obtain a solution D with an ethyl cellulose concentration of 50 mg / ml, adding the above-prepared oxaliplatin freeze-dried powder to obtain a solution E with an oxaliplatin concentration of 2 mg / ml, spreading 0.15 ml of the solution E on the PLGA membrane, and drying at 47°C to obtain a composite membrane A;
[0157] (3) dissolving 0.5% chitosan, 0.5% HPMC, and 0.5% gelatin in an acetic acid solution with a pH of 3 to obtain a solution F, spreading 0.4 g of the solution on a mold, and freeze-drying the solution in a vacuum dryer to obtain a chitosan adhesion layer;
[0158] (4) using 20 μl of solution C as an adhesive to bond the chitosan adhesive layer and the composite film A together to obtain a three-layer sustained-release composite film;
[0159] 3. In vitro release of three-layer composite sustained-release membrane
[0160] Place the composite membrane in 20 ml of release medium (PBS), place the release medium (PBS) containing the composite membrane on a constant temperature shaker at 37°C and 50 r / min, take samples at fixed points at 1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h, 96h, and 120h, centrifuge at 10000 r / min, and analyze the samples.
[0161] 4. Detection
[0162] The above samples were tested by high performance liquid chromatography; wherein the conditions of the high performance liquid chromatography were as follows:
[0163] The chromatogram was a Shiseido C18 column with a specification of 250x4.6mm; column temperature: 40°C; mobile phase: the aqueous phase was a 10% phosphoric acid solution diluted 6000 times with distilled water, and the organic phase was methanol; elution procedure: isocratic elution of the aqueous phase and the organic phase at a volume ratio of 98:2; mobile phase flow rate was 1mL / min; injection volume: 20μL; an ultraviolet detector was used: detection wavelength: 248nm.
[0164] Test results such as Figure 1 As shown. Figure 1 It can be seen that compared with free drugs, the sustained-release composite film prepared by the present invention has a drug sustained-release function, and can slowly release drugs within a certain period of time to achieve a long-term therapeutic effect, while avoiding the serious toxic effects of high-dose drug shock on normal tissues.
[0165] 5. In vivo adhesion test
[0166] A 1.5 cm wound was cut in the abdomen of BALB / c mice, the liver lobe was gently pulled out, and a 0.3 cm wound was cut on the surface of the liver lobe. The composite film was attached to the bleeding wound of the mouse liver lobe and pressed for 30 seconds. The abdominal wound was sutured. The mice were dissected after 14 days to observe the adhesion.
[0167] The results are as follows Figure 2 The results show that the sustained-release composite film prepared by the present invention can firmly adhere to the wound surface, and no displacement or shedding occurs after 14 days; the liver tissue around the adhesion site is in good condition, and no pathological changes such as redness and swelling occur.
[0168] A comprehensive comparison of the above embodiments 1-3 shows that the present application can achieve regulation of drug release rate by changing the amount of glycerol and medium-chain triglycerides when preparing a sustained-release composite film to adapt to different clinical drug dosage requirements, and has broad application prospects.
[0169] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A drug sustained-release composite film, comprising: An inner layer, the inner layer is an adhesive layer, and the inner layer comprises chitosan; a middle layer, the middle layer comprising lipid nanoparticles and ethylcellulose, wherein the lipid nanoparticles are loaded with drugs; The outer layer is a PLGA membrane.
2. The sustained-release composite film according to claim 1, wherein The membrane material of the lipid nanoparticles is phospholipid; Preferably, the membrane material of the lipid nanoparticles is egg yolk lecithin; More preferably, the membrane material of the lipid nanoparticles is egg yolk lecithin E80.
3. The sustained-release composite film according to any one of claims 1 to 2, wherein: In the lipid nanoparticles, the mass ratio of the drug to the membrane material of the lipid nanoparticles is 1:50-3:50, preferably 2:
50.
4. The sustained-release composite film according to any one of claims 1 to 3, wherein: The mass ratio of the drug to the ethyl cellulose is 1:50-3:50, preferably 2:
50.
5. The sustained-release composite film according to any one of claims 1 to 4, wherein: The inner layer also includes hydroxypropyl methylcellulose (HPMC) and gelatin; Preferably, the mass ratio of the chitosan, the hydroxypropyl methylcellulose and the gelatin is 1:1:
1.
6. The sustained-release composite film according to any one of claims 1 to 5, wherein: The sustained-release composite film has one or more technical features selected from the following (1)-(3): (1) The drug is a fat-soluble drug or a water-soluble drug; Preferably, the drug is oxaliplatin; (2) The molecular weight of the PLGA is 38000-54000, and PLA:PGA=50:50; (3) The viscosity of the chitosan is 200-400 mPa.s.
7. A method for preparing the drug sustained-release composite film according to any one of claims 1 to 6, comprising: (1) providing a PLGA solution and drying it to obtain a PLGA film, wherein the solvent of the PLGA solution is a volatile organic solvent; (2) providing an ethyl cellulose solution, wherein the solvent of the ethyl cellulose solution is an organic solvent; (3) adding the drug lipid nanoparticle lyophilized powder to the ethyl cellulose solution in step (2) to obtain a solution M; (4) spreading the solution M obtained in step (3) on the PLGA film obtained in step (1), and obtaining a composite film after drying; (5) providing a polymer solution and drying it to obtain a chitosan adhesion layer, wherein the polymer comprises chitosan; (6) bonding the chitosan adhesive layer obtained in step (5) to the composite film obtained in step (4) to obtain the drug sustained-release composite film; Preferably, the drug lipid nanoparticle lyophilized powder is prepared by the following method: 1) Providing a phospholipid aqueous solution and a drug aqueous solution; 2) mixing and drying the phospholipid aqueous solution and the drug aqueous solution to obtain drug lipid nanoparticle lyophilized powder.
8. The method according to claim 7, which has one or more technical features selected from the following (1)-(11): (1) In step (1), in the PLGA solution, the concentration of PLGA is 0.1-0.3 g / mL, preferably 0.2 g / mL; (2) In step (2), the organic solvent is selected from ethanol, glycerol, medium chain triglycerides (MCT) or any combination thereof; Preferably, the organic solvent is a mixed solvent of ethanol, glycerol and medium-chain triglycerides; More preferably, in the mixed solvent, the mass percentage concentration of the glycerol is 0.5-1%, and the mass percentage concentration of the medium-chain triglyceride is 2-3%; Most preferably, in the mixed solvent, the mass percentage concentration of the glycerol is 0.5%, and the mass percentage concentration of the medium-chain triglyceride is 2%; (3) In step (2), the concentration of ethyl cellulose in the ethyl cellulose solution is 45-55 mg / mL, preferably 50 mg / mL; (4) In step (3), the concentration of the drug in the solution M is 1-3 mg / mL, preferably 2 mg / mL; (5) In step (5), the polymer further comprises hydroxypropyl methylcellulose (HPMC) and gelatin; Preferably, in the polymer solution, the mass percentage concentrations of the chitosan, the hydroxypropyl methylcellulose and the gelatin are independently 0.4%-0.6%, preferably 0.5%; (6) In step (5), the solvent of the polymer solution is an acetic acid aqueous solution; Preferably, the pH of the acetic acid aqueous solution is 3; (7) In step 1), the concentration of the phospholipid in the phospholipid aqueous solution is 45-55 mg / mL, preferably 50 mg / mL; (8) In step 1), the phospholipid is egg yolk lecithin; Preferably, the phospholipid is egg yolk lecithin E80; (9) In step 1), the concentration of the drug in the aqueous drug solution is 1-3 mg / mL, preferably 2 mg / mL; (10) In step 1), the drug is a fat-soluble drug or a water-soluble drug; Preferably, the drug is oxaliplatin; (11) In step 2), the volume ratio of the phospholipid aqueous solution to the drug aqueous solution is 1:
1.
9. The method according to any one of claims 7 to 8, which has one or more technical features selected from the following (1) to (8): (1) In step (1), the molecular weight of the PLGA is 38000-54000, and PLA:PGA=50:50; (2) In step (1), the volatile organic solvent is selected from acetone, dichloromethane, chloroform or any combination thereof; Preferably, the volatile organic solvent is acetone, dichloromethane or chloroform; (3) In step (1), the drying is natural drying; (4) In step (4), the drying is oven drying, preferably oven drying at 47°C; (5) In step (5), the viscosity of the chitosan is 200-400 mPa.s; (6) In step (5), the drying is freeze-drying; (7) In step (6), the bonding is achieved using an adhesive; Preferably, the adhesive is the PLGA solution in step (1); (8) In step 2), the drying is vacuum drying or freeze drying.
10. Use of the drug sustained-release composite film according to any one of claims 1 to 6 or the drug sustained-release composite film prepared by the method according to any one of claims 7 to 9 in one or more of the following (1) to (4): (1) As a drug carrier; (2) As a tissue engineering scaffold; (3) for preparing a reagent for hemostasis; (4) Used for preparing a reagent, wherein the reagent is used for postoperative treatment of a tumor. Preferably, the tumor is a tumor treated by the drug loaded by the drug sustained-release composite membrane. Preferably, the drug is oxaliplatin.
Citation Information
Patent Citations
Sandwich type medical releasing film and preparing method thereof
CN101032473A
PLGA-chitosan one-way slow-release membrane and preparation method and use thereof
CN104382844A
Long-acting slow-release oral ulcer film and preparation method thereof
CN106109445A
Non-nanoparticulate application forms of macrolides
US20220395453A1
